About Macrophage scavenger receptor types I and II
Macrophage scavenger receptor types I and II (MSR1) is a protein
from Homo sapiens identified by UniProt accession
P21757, 451 residues long.
MolForge cross-references it against 0 known binders and
286 disease associations.
Target properties
| Protein name | Macrophage scavenger receptor types I and II |
| UniProt accession | P21757 |
| Gene | MSR1 |
| Organism | Homo sapiens |
| Length | 451 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (286)
Diseases linked to this target (Open Targets).
- IGF-1 measurement · score 0.49
- Barrett's esophagus · score 0.41
- Familial prostate cancer · score 0.41
- prostate carcinoma · score 0.41
- galectin-3-binding protein measurement · score 0.40
- ovarian cancer · score 0.39
- prostate adenocarcinoma · score 0.37
- familial prostate carcinoma · score 0.37
- protein measurement · score 0.36
- esophageal adenocarcinoma · score 0.34
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P21757-F1 | alphafold | PREDICTED | 67.41 | — |
Amino-acid sequence (451 residues)
MEQWDHFHNQ QEDTDSCSES VKFDARSMTA LLPPNPKNSP SLQEKLKSFK AALIALYLLV FAVLIPLIGI VAAQLLKWET KNCSVSSTNA NDITQSLTGK GNDSEEEMRF QEVFMEHMSN MEKRIQHILD MEANLMDTEH FQNFSMTTDQ RFNDILLQLS TLFSSVQGHG NAIDEISKSL ISLNTTLLDL QLNIENLNGK IQENTFKQQE EISKLEERVY NVSAEIMAMK EEQVHLEQEI KGEVKVLNNI TNDLRLKDWE HSQTLRNITL IQGPPGPPGE KGDRGPTGES GPRGFPGPIG PPGLKGDRGA IGFPGSRGLP GYAGRPGNSG PKGQKGEKGS GNTLTPFTKV RLVGGSGPHE GRVEILHSGQ WGTICDDRWE VRVGQVVCRS LGYPGVQAVH KAAHFGQGTG PIWLNEVFCF GRESSIEECK IRQWGTRACS HSEDAGVTCT L
Explore Macrophage scavenger receptor types I and II with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets